Newer risk markers and surrogate endpoints in atherosclerosis management
Related Experiment Videos
1Atherosclerosis Section, Baylor College of Medicine, Houston, Texas 77030, USA. cmb@bcm.tmc.edu
Abstract:
Risk markers that allow improved and individualized assessment of atherosclerotic disease risk and response to treatment are needed. Current candidate markers include cell adhesion molecules, such as intercellular adhesion molecule-1 and E-selectin, and inflammatory markers, such as C-reactive protein; advances in genomics and proteomics will suggest additional candidate markers. Noninvasive imaging procedures such as electron-beam computed tomography and magnetic resonance imaging also show considerable promise for monitoring disease status and response to treatment, and ultimately could provide surrogate endpoints for clinical trials of therapeutic interventions.
Related Concept Videos
Atherosclerosis III: Management
Coronary Artery Disease I: Introduction
Atherosclerosis IV: Nursing Management
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Atherosclerosis I: Introduction
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...